iRhythm Holdings, Inc. (IRTC) Presents at Bank of America Global Healthcare Conference 2026 Transcript

iRhythm said the final LCD landed in a favorable position after industry comments, with management saying it should increase access rather than limit it. The update also expanded potential patient indications, including systemic emboli and pre- and post-TAVR use cases. The tone was constructive for reimbursement/access and could modestly support the stock.

Analysis

The market is underestimating how much a favorable LCD can change the shape of iRhythm’s growth curve, not just the optics. Access expansion in higher-acuity cohorts matters because these patients tend to have richer utilization, higher physician urgency, and lower reimbursement friction, which should improve conversion efficiency and reduce the need for discounting to win volume. That is a better mix outcome than a simple unit uplift: it can drive better gross profit dollars per script and support operating leverage over the next 2-4 quarters.

The second-order winner is the company’s salesforce productivity and payer negotiation leverage. If the final policy is viewed as validating the clinical and economic case, referral friction falls and management can redeploy commercial spend toward expansion rather than defense; that should matter more than a one-day sentiment pop. Competitively, incumbents in ambulatory monitoring are disadvantaged if the addressable set broadens in categories where incumbency and workflow integration matter more than price, because switching costs rise once clinicians standardize on a preferred patch-based workflow.

The key risk is that this is a policy win, not yet a claims/data win. The stock can still de-rate if adoption fails to translate into observable volume acceleration within 1-2 quarters, or if MAC-level implementation creates local variation that blunts national upside. A smaller but real tail risk is that improved access invites faster scrutiny on overuse/utilization, which could reintroduce noise later in the year if CMS wants to see tighter clinical gating.

Consensus is likely too focused on the headline approval and not enough on the mix and operating leverage implications. The setup looks asymmetric because the upside can compound through both revenue growth and margin expansion, while downside requires either disappointing utilization follow-through or an administrative reversal that typically takes months, not days. That makes the next several print cycles the real catalyst window rather than the conference sound bite itself.

Key Decisions for Investors

• Go long IRTC on a 1-3 month horizon ahead of the next two earnings updates; thesis is policy-to-volume conversion with potential for multiple expansion if revenue growth re-accelerates and operating leverage shows through. Risk/reward is attractive if the stock is still trading off a 'good news, no change' mentality.
• Buy IRTC call spreads or outright calls expiring after the next quarterly print to capture a delayed fundamentals re-rating; prefer structures that pay for a move on evidence of utilization acceleration rather than just sentiment. Use width to limit premium burn if CMS implementation is slower than expected.
• Pair trade: long IRTC / short a basket of legacy ambulatory monitoring or lower-growth medtech names over the next 2 quarters. The relative trade expresses the view that iRhythm gets both a policy tailwind and better mix, while slower growers remain valuation vulnerable if sector multiples compress.
• Add on weakness if the stock fades on 'sell-the-news' tape following the conference, but only if volume confirms no fundamental deterioration; the market may be missing that reimbursement-policy wins tend to show up in bookings before reported revenue. Tighten risk if channel checks fail to improve within 30-45 days.
• If you own BAC as a conference venue/tactical beneficiary, do not extend the trade beyond the event; there is no evident second-order earnings implication, so it is a neutral event-only name.